Budesonide in the first line treatment of patients with autoimmune hepatitis

Ignasi Olivas; Marina Cobreros; María-Carlota Londoño; Álvaro Díaz-González

doi:10.1016/j.gastrohep.2021.11.012

Budesonide in the first line treatment of patients with autoimmune hepatitis

Gastroenterol Hepatol. 2022 Aug-Sep;45(7):561-570. doi: 10.1016/j.gastrohep.2021.11.012. Epub 2021 Dec 16.

[Article in English, Spanish]

Authors

Ignasi Olivas¹, Marina Cobreros², María-Carlota Londoño¹, Álvaro Díaz-González³

Affiliations

¹ Liver Unit, Hospital Clínic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERehd, Universitat de Barcelona, Barcelona, Spain.
² Digestive Diseases Department, Marqués de Valdecilla University Hospital, Instituto de investigación sanitaria Valdecilla (IDIVAL), Santander, Spain.
³ Digestive Diseases Department, Marqués de Valdecilla University Hospital, Instituto de investigación sanitaria Valdecilla (IDIVAL), Santander, Spain. Electronic address: [email protected].

PMID: 34923033
DOI: 10.1016/j.gastrohep.2021.11.012

Abstract

Budesonide is a glucocorticoid characterized by its local action, with a low systemic bioavailability. Since the original trial comparing budesonide with prednisone in 2010, it is recommended as an effective alternative for the treatment of non-severe acute or chronic autoimmune hepatitis. In this document, we review the general pharmacologic properties of glucocorticoids, the available evidence for the use of budesonide as first line option for autoimmune hepatitis as well as the safety profile of the drug.

Keywords: Autoimmune hepatitis; Biochemical remission; Budesonida; Budesonide; Hepatitis autoinmune; Prednisona; Prednisone; Remisión bioquímica.

Publication types

Review

MeSH terms

Budesonide* / therapeutic use
Glucocorticoids / therapeutic use
Hepatitis, Autoimmune* / drug therapy
Humans
Prednisone / therapeutic use

Substances

Glucocorticoids
Budesonide
Prednisone